Literature DB >> 21324796

Unknown primary cancer of the head and neck: a multidisciplinary approach.

Laura Cerezo1, Eduardo Raboso, Ana Isabel Ballesteros.   

Abstract

The management of patients with cervical lymph node metastases from an unknown primary cancer (CUP) remains a matter of controversy. Although new advanced diagnostic tools, such as positron emission tomography, have recently been introduced in oncology, the frequency of this tumour entity in clinical practice means it is still relevant. Recently introduced molecular profiling platforms may provide biological classification for the primary tissue of origin as well as insights into the pathophysiology of this clinical entity, including the characterisation of the Epstein-Barr virus and human papilloma virus genomas in the metastatic cervical nodes. Due to the lack of randomised trials, a standard therapy has not been identified yet. Although neck dissection followed by post-operative radiotherapy is the most generally accepted approach, there are other curative options that can be used in some patients: neck dissection alone, nodal excision followed by post-operative radiotherapy or radiotherapy alone. A major controversy remains in the target radiation volumes that range from ipsilateral neck irradiation to prophylactic irradiation of all potential mucosal sites and both sides of the neck. Finally, the administration of concurrent chemotherapy is currently being advised for patients with adverse prognostic factors.

Entities:  

Mesh:

Year:  2011        PMID: 21324796     DOI: 10.1007/s12094-011-0624-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  52 in total

Review 1.  Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience.

Authors:  V Grégoire; E Coche; G Cosnard; M Hamoir; H Reychler
Journal:  Radiother Oncol       Date:  2000-08       Impact factor: 6.280

2.  Diagnosis and management of carcinoma of unknown primary in the head and neck.

Authors:  Wolfgang J Issing; Behsad Taleban; Stefan Tauber
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-04-09       Impact factor: 2.503

3.  Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection.

Authors:  H S Erkal; W M Mendenhall; R J Amdur; D B Villaret; S P Stringer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-05-01       Impact factor: 7.038

Review 4.  Cancer of unknown primary site: missing primary or missing biology?

Authors:  George Pentheroudakis; Evangelos Briasoulis; Nicholas Pavlidis
Journal:  Oncologist       Date:  2007-04

5.  Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.

Authors:  John D Hainsworth; David R Spigel; Dana S Thompson; Patrick B Murphy; Cassie M Lane; David M Waterhouse; Yuval Naot; F Anthony Greco
Journal:  Oncologist       Date:  2009-12-04

6.  Metastatic carcinoma of the neck of unknown primary origin: evolution and efficacy of the modern workup.

Authors:  Joshua D Waltonen; Enver Ozer; Nathan C Hall; David E Schuller; Amit Agrawal
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-10

7.  Diagnostic strategies in cervical carcinoma of an unknown primary (CUP).

Authors:  Inge Haas; Thomas K Hoffmann; Rainer Engers; Uwe Ganzer
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-05-01       Impact factor: 2.503

Review 8.  Human papillomavirus in HNSCC: recognition of a distinct disease type.

Authors:  Laura Vidal; Maura L Gillison
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

9.  Metastatic carcinoma in the cervical lymph nodes from an occult primary: a conservative approach to the role of radiotherapy.

Authors:  R G Glynne-Jones; A K Anand; T E Young; R J Berry
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-02       Impact factor: 7.038

Review 10.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more
  6 in total

1.  Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.

Authors:  Toshiya Maebayashi; Naoya Ishibashi; Takuya Aizawa; Masakuni Sakaguchi; Tsutomu Saito; Jiro Kawamori; Yoshiaki Tanaka; Yukari Hirotani; Taku Homma
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

2.  Transoral robotic approach to carcinoma of unknown primary.

Authors:  Kasim Durmus; Sanjeet V Rangarajan; Matthew O Old; Amit Agrawal; Theodoros N Teknos; Enver Ozer
Journal:  Head Neck       Date:  2013-09-02       Impact factor: 3.147

3.  Angiosarcoma of the scalp diagnosed by the presence of neck inflammation: a case report.

Authors:  Rei Karube; Hiroyoshi Sasaki; Keiji Shinozuka; Yasuhiro Fujisawa; Toru Yanagawa; Kenji Yamagata; Kojiro Onizawa; Fujio Otsuka; Hiroki Bukawa
Journal:  Int J Oral Sci       Date:  2012-06-15       Impact factor: 6.344

Review 4.  Cancers of unknown primary origin: current perspectives and future therapeutic strategies.

Authors:  Giulia Maria Stella; Rebecca Senetta; Adele Cassenti; Margherita Ronco; Paola Cassoni
Journal:  J Transl Med       Date:  2012-01-24       Impact factor: 5.531

5.  Human papillomavirus and p53 expression in cancer of unknown primary in the head and neck region in relation to clinical outcome.

Authors:  Lars Sivars; Anders Näsman; Nikolaos Tertipis; Andrea Vlastos; Torbjörn Ramqvist; Tina Dalianis; Eva Munck-Wikland; Sushma Nordemar
Journal:  Cancer Med       Date:  2014-02-10       Impact factor: 4.452

6.  Fluid biopsy for circulating tumor cells in an occult ovarian cancer patient exhibiting bilateral supraclavicular lymph node metastases: A case report.

Authors:  Shizhi He; Pingdong Li; Xiaohong Chen; Zhenkun Yu
Journal:  Oncol Lett       Date:  2013-05-24       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.